28 February 2017
(Oxford, UK, 28th February 2017) Immunocore Limited, a world-leading biotechnology company developing novel TCR-based biological drugs to treat cancer, infectious diseases and autoimmune diseases, announced today that it will present at the Cowen and Company 37th Annual Healthcare Conference in Boston, MA.
Eva-Lotta Allan, Immunocore’s Chief Business Officer, is scheduled to present at The Boston Marriott Copley Place on Tuesday, March 7 at 5:00pm ET. Ms. Allan’s presentation will provide an overview of the Company’s world leading and highly innovative immuno-oncology technology, and an update on the progress of Immunocore’s lead programme, IMCgp100.
Please click on the link below to download the full Press Release: